ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Sets Rules For Omics Studies

October 18, 2013

Give New Investigators “Special Consideration,” Advisors Tell NCI

June 28, 2002

What the Physician Pay Report Won’t Tell You

April 11, 2014

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014

NCI News Roundup: clinical Trials Initiatives Explained in Lectures Available Online

June 11, 1999

Defying critics, von Eschenbach describes hands-on role at NCI while running FDA. NCI is unified behind 2015 goal, he says.

December 9, 2005